Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study

Aims The goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in Korean patients with schizophrenia who showed stable symptoms. Methods In this 8‐week, open‐label, prospective, non‐randomized, multicenter study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms, were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2–7‐week washout period. Results Steady decreases were observed on the Montgomery–Asberg Depression Rating Scale, the Calgary Depression Scale for Schizophrenia, the Positive and Negative Syndrome Scale, and the Clinical Global Impression‐Severity Scale scores. The Montgomery–Asberg Depression Rating Scale score was 20.26 ± 4.77 at baseline and 12.21 ± 7.94 at the end‐point (P